EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs).
EZH2 (Enhancer of Zest homolog)
epigenetic treatment
histone modification
pancreatic neuroendocrine neoplasms
tumor treatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Oct 2021
07 Oct 2021
Historique:
received:
14
09
2021
revised:
28
09
2021
accepted:
01
10
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Pancreatic neuroendocrine neoplasms are epigenetically driven tumors, but therapies against underlying epigenetic drivers are currently not available in the clinical practice. We aimed to investigate EZH2 (Enhancer of Zest homolog) expression in PanNEN and the impact of EZH2 inhibition in three different PanNEN preclinical models. EZH2 expression in PanNEN patient samples (
Identifiants
pubmed: 34638497
pii: cancers13195014
doi: 10.3390/cancers13195014
pmc: PMC8508156
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Swill Cancer League
ID : KLS-4227-08-2017
Organisme : SNF Marie Heim-Vögtlin
ID : PMPDP3_164484
Organisme : Tumour Forschung Bern
Références
Commun Biol. 2020 Dec 7;3(1):740
pubmed: 33288854
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
Lancet Oncol. 2020 Nov;21(11):1423-1432
pubmed: 33035459
J Biol Chem. 2003 Oct 31;278(44):42750-60
pubmed: 12917399
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Nat Commun. 2017 Oct 3;8(1):767
pubmed: 28974674
Nature. 2002 Oct 10;419(6907):624-9
pubmed: 12374981
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Neuroendocrinology. 2021;111(3):273-287
pubmed: 32241015
Pharm Stat. 2011 Mar-Apr;10(2):128-34
pubmed: 22328315
Lancet Haematol. 2018 Dec;5(12):e604-e605
pubmed: 30501864
Lancet Haematol. 2020 Apr;7(4):e309-e319
pubmed: 32145771
Hum Pathol. 2018 Jul;77:70-79
pubmed: 29596894
Nat Med. 2016 Feb;22(2):128-34
pubmed: 26845405
Gut. 2021 Sep;70(9):1768-1781
pubmed: 33692095
Mol Biotechnol. 2013 Nov;55(3):217-26
pubmed: 23709336
Endocr Relat Cancer. 2017 Sep;24(9):R315-R334
pubmed: 28710117
Science. 2011 Mar 4;331(6021):1199-203
pubmed: 21252315
Gastroenterology. 2014 Feb;146(2):453-60.e5
pubmed: 24148618
Nature. 2012 Dec 6;492(7427):108-12
pubmed: 23051747
Cell. 1996 Aug 9;86(3):353-64
pubmed: 8756718
Clin Cancer Res. 2019 Dec 15;25(24):7331-7339
pubmed: 31471312
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Neuroendocrinology. 2021;111(9):883-894
pubmed: 33002892
J Hematol Oncol. 2020 Jul 28;13(1):104
pubmed: 32723346
Genes Dev. 2009 Apr 15;23(8):975-85
pubmed: 19390090
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6662-70
pubmed: 25400745
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
Nature. 1985 May 9-15;315(6015):115-22
pubmed: 2986015
Mol Cancer Res. 2018 Mar;16(3):496-507
pubmed: 29330294
Gastroenterology. 2018 Jun;154(8):2060-2063.e8
pubmed: 29486199
Cancer Discov. 2016 Sep;6(9):1006-21
pubmed: 27312177
EMBO J. 2003 Oct 15;22(20):5323-35
pubmed: 14532106
Lancet Oncol. 2020 Nov;21(11):1433-1442
pubmed: 33035457
Lancet Oncol. 2019 Jun;20(6):806-815
pubmed: 31036468